Does the media favor ZVRA or KRRO?

In the previous week, Korro Bio had 4 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Korro Bio and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.63 beat Korro Bio's score of -0.13 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, IVA or KRRO?

Korro Bio has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 139.87 -$400.67M N/A N/A Korro Bio $6.39M 28.66 -$117.26M -$11.67 N/A

Is IVA or KRRO more profitable?

Inventiva has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Inventiva's return on equity of 0.00% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Korro Bio -1,834.48% -117.86% -71.04%

Does the media prefer IVA or KRRO?

In the previous week, Korro Bio had 5 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Korro Bio and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat Korro Bio's score of -0.13 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, KRRO or CYRX?

CryoPort has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 28.66 -$117.26M -$11.67 N/A CryoPort $176.18M 4.58 $78.30M $1.35 11.85

Is KRRO or CYRX more profitable?

CryoPort has a net margin of 41.57% compared to Korro Bio's net margin of -1,834.48%. CryoPort's return on equity of -7.92% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -117.86% -71.04% CryoPort 41.57% -7.92% -4.79%

Does the media favor KRRO or CYRX?

In the previous week, Korro Bio had 2 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Korro Bio and 5 mentions for CryoPort. CryoPort's average media sentiment score of 1.03 beat Korro Bio's score of -0.13 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AURA or KRRO more profitable?

Aura Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Aura Biosciences' return on equity of -78.12% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Korro Bio -1,834.48% -117.86% -71.04%

Does the media prefer RLMD or KRRO?

In the previous week, Korro Bio had 4 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Korro Bio and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.93 beat Korro Bio's score of -0.13 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Korro Bio (KRRO) Competitors

$12.70 +0.53 (+4.35%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$12.66 -0.04 (-0.31%)

As of 06/26/2026 07:14 PM Eastern

Compare

KRRO vs. ZVRA, IVA, CYRX, AURA, and RLMD

Should you buy Korro Bio stock or one of its competitors? MarketBeat compares Korro Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Korro Bio include Zevra Therapeutics (ZVRA), Inventiva (IVA), CryoPort (CYRX), Aura Biosciences (AURA), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

How does Korro Bio compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Zevra Therapeutics has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.51	$83.23M	$1.99	6.79
Korro Bio	$6.39M	28.66	-$117.26M	-$11.67	N/A

In the previous week, Korro Bio had 4 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Korro Bio and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.63 beat Korro Bio's score of -0.13 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics presently has a consensus price target of $29.29, suggesting a potential upside of 116.61%. Korro Bio has a consensus price target of $16.71, suggesting a potential upside of 31.61%. Given Zevra Therapeutics' higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Zevra Therapeutics has a net margin of 101.58% compared to Korro Bio's net margin of -1,834.48%. Zevra Therapeutics' return on equity of 51.49% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Korro Bio	-1,834.48%	-117.86%	-71.04%

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Summary

Zevra Therapeutics beats Korro Bio on 10 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Inventiva?

Inventiva (NASDAQ:IVA) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Inventiva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Korro Bio has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	139.87	-$400.67M	N/A	N/A
Korro Bio	$6.39M	28.66	-$117.26M	-$11.67	N/A

Inventiva has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Inventiva's return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Korro Bio	-1,834.48%	-117.86%	-71.04%

Inventiva currently has a consensus price target of $16.56, indicating a potential upside of 384.93%. Korro Bio has a consensus price target of $16.71, indicating a potential upside of 31.61%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

In the previous week, Korro Bio had 5 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Korro Bio and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat Korro Bio's score of -0.13 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 4.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Inventiva beats Korro Bio on 9 of the 13 factors compared between the two stocks.

How does Korro Bio compare to CryoPort?

Korro Bio (NASDAQ:KRRO) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Korro Bio has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

In the previous week, Korro Bio had 2 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Korro Bio and 5 mentions for CryoPort. CryoPort's average media sentiment score of 1.03 beat Korro Bio's score of -0.13 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	28.66	-$117.26M	-$11.67	N/A
CryoPort	$176.18M	4.58	$78.30M	$1.35	11.85

CryoPort has a net margin of 41.57% compared to Korro Bio's net margin of -1,834.48%. CryoPort's return on equity of -7.92% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
CryoPort	41.57%	-7.92%	-4.79%

Korro Bio presently has a consensus target price of $16.71, indicating a potential upside of 31.61%. CryoPort has a consensus target price of $15.11, indicating a potential downside of 5.54%. Given Korro Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Korro Bio is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 10.1% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

CryoPort beats Korro Bio on 10 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 4.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aura Biosciences has higher earnings, but lower revenue than Korro Bio. Aura Biosciences is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Korro Bio	$6.39M	28.66	-$117.26M	-$11.67	N/A

Aura Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market.

Aura Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Aura Biosciences' return on equity of -78.12% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Korro Bio	-1,834.48%	-117.86%	-71.04%

In the previous week, Korro Bio had 6 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Korro Bio and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.87 beat Korro Bio's score of -0.13 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Aura Biosciences	Very Positive
Korro Bio	Neutral

Aura Biosciences currently has a consensus target price of $20.50, suggesting a potential upside of 192.86%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 31.61%. Given Aura Biosciences' higher possible upside, equities research analysts plainly believe Aura Biosciences is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

Aura Biosciences beats Korro Bio on 9 of the 15 factors compared between the two stocks.

How does Korro Bio compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Relmada Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Relmada Therapeutics' return on equity of -71.22% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 79.37%. Korro Bio has a consensus price target of $16.71, suggesting a potential upside of 31.61%. Given Relmada Therapeutics' higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Relmada Therapeutics has higher earnings, but lower revenue than Korro Bio. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Korro Bio	$6.39M	28.66	-$117.26M	-$11.67	N/A

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Relmada Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market.

In the previous week, Korro Bio had 4 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Korro Bio and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.93 beat Korro Bio's score of -0.13 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relmada Therapeutics beats Korro Bio on 9 of the 15 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRRO vs. The Competition

Export

Metric	Korro Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$183.17M	$3.04B	$7.04B	$12.18B
Dividend Yield	N/A	1.77%	2.66%	6.24%
P/E Ratio	N/A	19.54	25.90	24.17
Price / Sales	28.66	679.54	600.60	118.47
Price / Cash	N/A	57.21	47.95	55.62
Price / Book	2.33	4.21	10.78	6.36
Net Income	-$117.26M	$64.45M	$3.58B	$337.99M
7 Day Performance	-2.23%	2.22%	2.22%	0.10%
1 Month Performance	-5.22%	-0.77%	-0.09%	-1.28%
1 Year Performance	5.57%	29.70%	34.39%	27.68%

Korro Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRRO Korro Bio	2.6727 of 5 stars	$12.70 +4.4%	$16.71 +31.6%	+5.6%	$183.17M	$6.39M	N/A	70	News Coverage Insider Trade High Trading Volume
ZVRA Zevra Therapeutics	4.4269 of 5 stars	$12.95 +2.4%	$29.29 +126.1%	+50.2%	$765.60M	$106.47M	6.51	20	Analyst Forecast
IVA Inventiva	2.7977 of 5 stars	$3.68 +4.8%	$16.56 +349.9%	+12.5%	$764.37M	$5.07M	N/A	100	High Trading Volume
CYRX CryoPort	3.8243 of 5 stars	$14.70 -0.5%	$15.11 +2.8%	+115.9%	$740.91M	$182.94M	10.89	1,186	News Coverage Positive News
AURA Aura Biosciences	2.2379 of 5 stars	$7.11 +2.3%	$20.50 +188.3%	+11.5%	$735.10M	N/A	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Korro Bio (KRRO) Competitors

KRRO vs. ZVRA, IVA, CYRX, AURA, and RLMD

How does Korro Bio compare to Zevra Therapeutics?

Summary

How does Korro Bio compare to Inventiva?

Summary

How does Korro Bio compare to CryoPort?

Summary

How does Korro Bio compare to Aura Biosciences?

Summary

How does Korro Bio compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Korro Bio (KRRO) Competitors

KRRO vs. ZVRA, IVA, CYRX, AURA, and RLMD

How does Korro Bio compare to Zevra Therapeutics?

Which has better valuation & earnings, ZVRA or KRRO?

Does the media favor ZVRA or KRRO?

Do analysts rate ZVRA or KRRO?

Is ZVRA or KRRO more profitable?

Do insiders and institutionals have more ownership in ZVRA or KRRO?

Which has more volatility & risk, ZVRA or KRRO?

Summary

How does Korro Bio compare to Inventiva?

Which has more risk & volatility, IVA or KRRO?

Which has higher valuation and earnings, IVA or KRRO?

Is IVA or KRRO more profitable?

Do analysts recommend IVA or KRRO?

Does the media prefer IVA or KRRO?

Do insiders and institutionals believe in IVA or KRRO?

Summary

How does Korro Bio compare to CryoPort?

Which has more volatility and risk, KRRO or CYRX?

Does the media favor KRRO or CYRX?

Which has preferable valuation and earnings, KRRO or CYRX?

Is KRRO or CYRX more profitable?

Do analysts recommend KRRO or CYRX?

Do insiders & institutionals believe in KRRO or CYRX?

Summary

How does Korro Bio compare to Aura Biosciences?

Do institutionals and insiders hold more shares of AURA or KRRO?

Which has preferable valuation & earnings, AURA or KRRO?

Which has more volatility & risk, AURA or KRRO?

Is AURA or KRRO more profitable?

Does the media favor AURA or KRRO?

Do analysts rate AURA or KRRO?

Summary

How does Korro Bio compare to Relmada Therapeutics?

Is RLMD or KRRO more profitable?

Do analysts rate RLMD or KRRO?

Which has preferable valuation and earnings, RLMD or KRRO?

Do insiders and institutionals hold more shares of RLMD or KRRO?

Which has more risk & volatility, RLMD or KRRO?

Does the media prefer RLMD or KRRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools